EVO revenueFY2025€788.37M
- FY YoY
- -1.1%
- 5Y CAGR
- +9.5%
EVO revenue was €788.37M for fiscal 2025 (ended Dec 31, 2025), down 1.1% from fiscal 2024. Compound annual growth was +9.5% over 5 years. It rose in 5 of the last 6 fiscal years.
Evotec SE (EVO) financials
For fiscal 2025 (ended Dec 31, 2025), Evotec SE reported €788.37M of revenue and -€103.52M of net income. Figures are in EUR, the currency of its SEC filings.
- Revenue, FY2025
- €788.37M
- Revenue growth, YoY
- -1.1%
- Net income, FY2025
- -€103.52M
- Net margin
- -13.1%
- Free cash flow, FY2025
- -€81.72M
- EPS, diluted, FY2025
- -€0.58
- Cash
- €418.52M
- Total debt
- €276.40M
FY2019FY2025
FY2019FY2025
FY2019FY2025
EVO revenue and earnings growth
EVO net incomeFY2025-€103.52M
EVO net income was -€103.52M for fiscal 2025 (ended Dec 31, 2025), compared with -€196.08M in fiscal 2024.
EVO EPSFY2025-€0.58
EVO diluted EPS was -€0.58 for fiscal 2025 (ended Dec 31, 2025), compared with -€1.11 in fiscal 2024.
EVO free cash flowFY2025-€81.72M
EVO free cash flow was -€81.72M for fiscal 2025 (ended Dec 31, 2025), compared with -€99.25M in fiscal 2024.
Income statement
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 |
|---|---|---|---|---|---|---|---|
| Revenue | €788.37M | €796.97M | €781.43M | €751.45M | €618.03M | €500.92M | €446.44M |
| Cost of revenue | €674.15M | €682.09M | €606.38M | €577.38M | €466.49M | €375.18M | €313.55M |
| Gross profit | €114.22M | €114.88M | €175.05M | €174.06M | €151.54M | €125.74M | €132.89M |
| Research and development | €37.51M | €50.86M | €68.53M | €76.64M | €72.20M | €63.95M | €58.43M |
| Selling, general and admin | €175.97M | €188.20M | €169.61M | €156.19M | €105.44M | €77.20M | €66.43M |
| Operating income | -€56.22M | -€142.52M | -€47.51M | €20.85M | €41.00M | €48.56M | €62.71M |
| Interest expense | - | - | - | €13.15M | €9.25M | €8.46M | €7.46M |
| Pre-tax income | -€86.77M | -€193.98M | -€80.59M | -€153.96M | €236.98M | €25.84M | €56.67M |
| Income tax | €16.75M | €2.10M | €3.32M | €21.70M | €21.47M | €19.56M | €19.36M |
| Net income | -€103.52M | -€196.08M | -€83.91M | -€175.66M | €215.51M | €6.28M | €38.16M |
| EPS, basic | -€0.58 | -€1.11 | -€0.47 | -€0.99 | €1.30 | €0.04 | €0.25 |
| EPS, diluted | -€0.58 | -€1.11 | -€0.47 | -€0.99 | €1.30 | €0.04 | €0.25 |
| Diluted shares | 177.6M | 177.3M | 176.9M | 176.7M | 166.4M | 153.8M | 149.7M |
Balance sheet
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 |
|---|---|---|---|---|---|---|---|
| Cash and equivalents | €418.52M | €306.39M | €510.91M | €415.15M | €699.33M | €422.58M | €277.03M |
| Receivables | €135.96M | €116.32M | €98.40M | €171.80M | - | - | - |
| Inventory | €29.32M | €31.12M | €30.89M | €29.82M | €25.79M | €13.59M | - |
| Current assets | €762.95M | €681.96M | €903.16M | €1.07B | €1.10B | €658.84M | - |
| Goodwill | €272.37M | €282.85M | €275.63M | €274.82M | €257.57M | €247.37M | €255.92M |
| Total assets | €1.71B | €1.91B | €2.25B | €2.26B | €2.24B | €1.46B | - |
| Current liabilities | €368.07M | €344.58M | €464.57M | €337.71M | €324.52M | €208.46M | - |
| Short-term debt | - | - | - | €1.56M | €36.14M | €15.39M | - |
| Long-term debt | - | - | - | €328.30M | €326.34M | €331.02M | - |
| Total debt | €276.40M | €287.56M | €437.06M | €329.85M | €362.48M | €346.41M | - |
| Total liabilities | €900.24M | €959.98M | €1.13B | €1.07B | €857.48M | €737.88M | - |
| Shareholders' equity | €813.70M | €952.52M | €1.12B | €1.19B | €1.38B | €724.46M | €478.61M |
Cash flow
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -€9.18M | €18.22M | €36.44M | €205.81M | €126.60M | €44.72M | €42.22M |
| Capital expenditures | €72.54M | €117.47M | €213.32M | €181.35M | €118.94M | €99.07M | €31.32M |
| Free cash flow | -€81.72M | -€99.25M | -€176.88M | €24.46M | €7.66M | -€54.35M | €10.89M |
| Investing cash flow | €171.59M | -€71.19M | -€13.29M | -€412.80M | -€242.79M | -€155.09M | -€86.63M |
| Financing cash flow | -€37.63M | -€161.42M | €71.96M | -€58.15M | €393.01M | €246.41M | €211.26M |
| Share repurchases | €1.55M | - | - | - | - | - | - |
| Stock-based compensation | €3.78M | €5.04M | €9.63M | €9.92M | €7.80M | €5.29M | €3.65M |
| Depreciation and amortization | €99.48M | €101.62M | €92.98M | €83.20M | €70.40M | - | - |
Key ratios
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 |
|---|---|---|---|---|---|---|---|
| Revenue growth, YoY | -1.1% | 2.0% | 4.0% | 21.6% | 23.4% | 12.2% | - |
| Net income growth, YoY | - | - | - | - | 3332.8% | -83.5% | - |
| EPS growth, YoY | - | - | - | - | 3150.0% | -84.0% | - |
| Gross margin | 14.5% | 14.4% | 22.4% | 23.2% | 24.5% | 25.1% | 29.8% |
| Operating margin | -7.1% | -17.9% | -6.1% | 2.8% | 6.6% | 9.7% | 14.0% |
| Net margin | -13.1% | -24.6% | -10.7% | -23.4% | 34.9% | 1.3% | 8.5% |
| Free cash flow margin | -10.4% | -12.5% | -22.6% | 3.3% | 1.2% | -10.9% | 2.4% |
| Return on equity | -12.7% | -20.6% | -7.5% | -14.8% | 15.6% | 0.9% | 8.0% |
| Return on assets | -6.0% | -10.3% | -3.7% | -7.8% | 9.6% | 0.4% | - |
| Current ratio | 2.07 | 1.98 | 1.94 | 3.18 | 3.39 | 3.16 | - |
| Debt to equity | 0.34 | 0.30 | 0.39 | 0.28 | 0.26 | 0.48 | - |
Source: XBRL data Evotec SE files with the SEC, latest filing dated Apr 8, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
Per-share figures are as filed. The filings show no stock split in these periods.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
Foreign private issuers file annual reports with the SEC, so there are no quarterly statements here.
EVO peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| EVO | €788.37M | -1.1% | -€103.52M | -13.1% | $601.2M |
| LLY | $86.46B | +45.5% | $27.58B | 31.9% | $1.27T |
| JNJ | $99.33B | +7.8% | $16.09B | 16.2% | $664.95B |
| ABBV | $66.01B | +10.7% | $10.34B | 15.7% | $514.92B |
| MRK | $67.38B | +4.9% | $2.45B | 3.6% | $361.71B |
| NVS | $54.53B | +8.4% | $13.98B | 25.6% | $310.17B |
| AZN | $58.74B | +8.6% | $10.22B | 17.4% | $289.10B |
| ABT | $48.23B | +10.0% | $4.70B | 9.7% | $190.39B |
| NVO | DKK 309.06B | +6.4% | DKK 102.43B | 33.1% | $178.51B |
EVO FAQ
9 questionsWhat is EVO revenue?
Evotec SE (EVO) reported €788.37M of revenue for fiscal 2025 (ended Dec 31, 2025). That is down 1.1% from the year before.Is EVO profitable?
No. Evotec SE reported a net loss of €103.52M for fiscal 2025 (ended Dec 31, 2025).How much cash and debt does EVO have?
Evotec SE reported €418.52M in cash and cash equivalents and €276.40M of debt on its most recent balance sheet in SEC filings.How fast is EVO revenue growing?
Evotec SE's revenue changed -1.1% in fiscal 2025, to €788.37M. Its compound annual growth rate was +9.5% over 5 years.What is EVO gross margin?
Evotec SE's gross profit was €114.22M on €788.37M of revenue for fiscal 2025 (ended Dec 31, 2025), a gross margin of 14.5%.What is EVO free cash flow?
Evotec SE generated -€81.72M of free cash flow for fiscal 2025 (ended Dec 31, 2025), which is operating cash flow of -€9.18M less capital expenditures.What is EVO earnings per share?
Diluted earnings per share were -€0.58 for fiscal 2025 (ended Dec 31, 2025), from SEC filings, restated for any stock split those filings show.When did EVO last report financial results?
The latest statements here come from Evotec SE's 20-F filed on Apr 8, 2026, covering the period ended Dec 31, 2025.Where does this EVO financial data come from?
Quantisnow builds these statements from the structured XBRL data Evotec SE files with the SEC. It is provided for information only and is not investment advice.